Cytorex Biosciences

Cytorex Biosciences is a Florida-based biopharma company that owns a patented technology (U.S. Patent 7,141,251), utilizing an unprecedented approach to cancer treatment: inorganic acids as active substances. Its lead compound, Cytoreg®, is a combination of four inorganic acids and two organic acids in water, with the fluoride ion (F- ion) from hydrofluoric acid acting as the active agent. Cytoreg® will target and kill cancer cells without affecting normal cells, making it a highly effective and safe product for use in human cancer patients. The first indication for Cytoreg® is glioblastoma multiforme, a malignant brain tumor with an extremely low cure rate. Due to its very low molecular weight, Cytoreg® can cross the blood-brain barrier.